基于汉密尔顿焦虑抑郁量表评价加味逍遥散两种剂型调节围绝经期情绪障碍的疗效差异

Evaluation of the efficacy of Jiawei Xiaoyao Powder in regulating perimenopausal mood disorders based on HAMA and HAMD

目的:在前期加味逍遥丸治疗围绝经期情绪障碍具有比较优势的基础上,基于汉密尔顿焦虑抑郁量表(HAMA、HAMD)探讨其颗粒剂和水丸剂两种剂型间的疗效差异。方法:将75例围绝经期情绪障碍女性患者随机分为帕罗西汀组(A组)、加味逍遥丸组(B组)和加味逍遥颗粒组(C组),分别对应采用帕罗西汀、加味逍遥丸和加味逍遥颗粒治疗8周。在治疗前后对所有患者各进行1次HAMA、HAMD评定,并在观察期结束时进行TESS评定。结果:HAMA总分差及HAMD睡眠、躯体因子分差:3种治疗方法均有改善(P<0.01),且相互间差异无统计学意义(P>0.05);HAMD总分差:后二组均优于A组(P<0.05),且B、C二组之间差异无统计学意义(P>0.05);TESS评分:B、C两组与A组比较,差异均有统计学意义(P<0.01),且评分均小于A组,而B、C二组间差异无统计学意义(P>0.05)。结论:加味逍遥散的两种剂型间疗效差异无统计学意义,考虑到帕罗西汀的不良反应,在治疗围绝经期情绪障碍方面,加味逍遥散的两种剂型都值得推荐。

Objective:Based on the comparative advantages of Jiawei Xiaoyao Pill in the treatment of perimenopausal emotional disorders,to explore the difference between its granules and water pills based on anxiety and depression scale.Methods:Seventy-five perimenopausal women with emotional disorders were randomly divided into three groups:group A,group B and group C.Paroxetine,Jiawei Xiaoyao Pill and Jiawei Xiaoyao Granule were respectively used for 8 weeks.All patients were assessed with Hamilton Anxiety Scale(HAMA)and Hamilton Depression Scale(HAMD)once before and after treatment,and TESS was performed at the end of the observation period.Results:HAMA total score difference and HAMD sleep and somatic factor score difference:the three treatment methods were improved(P<0.01),and there was no statistical difference among them(P<0.05);HAMD total score difference:the latter two groups were better than group A(P<0.05),and there was no statistical difference between group B and C(P>0.05);TESS score:there was statistical significance between group B and group C and group A(P<0.01),and the scores were lower than those of group A(P<0.01).There was no significant difference between group A and group B and C(P>0.05).Conclusion:There is no significant difference between the two dosage forms of Jiawei Xiaoyao Powder.Considering the adverse reactions of paroxetine,the two dosage forms of Jiawei Xiaoyao Powder are recommended for the treatment of perimenopausal emotional disorders.